EUVIMEDEUVIMED entdecken
Multizentrische Studie

Real-world Efficacy and Safety of Flumatinib as the First-line Treatment in Patients With de novo Philadelphia-positive Acute Lymphoblastic Leukemia

Zhibo Zhang, Jia Yin, Jun Wang, Xuefeng He, Xiaohui Hu, Haiwen Huang, Limin Liu, Miao Miao, Ying Wang, Huiying Qiu, Xiaowen Tang, Depei Wu und 2 weitere

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.04.010 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Zhibo Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suz…. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Combined Chemotherapy Protocols, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The real-world data of flumatinib, a China-developed second-generation tyrosine kinase inhibitors (TKI), on Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is limited. This study evaluated the efficacy and safety of flumatinib combined with chemotherapy as first-line therapy for Ph+ ALL. METHODS: This multicenter retrospective study included 65 adults with de novo Ph+ ALL treated with flumatinib (600 mg/day) plus intensive chemotherapy. Outcomes included complete remission (CR), CR with minimal residual disease negativity detected by multiparameter flow cytometry (CR flow-), overall survival (OS), event-free survival (EFS), and adverse events (AEs). Survival and prognostic factors were analyzed using the Kaplan-Meier method. RESULTS: CR and CR flow- were achieved in 96.9% (63/65) and 58.5% (38/65) of patients postinduction, respectively. At 24 months, OS and EFS were 87.4% and 62.6%, respectively. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) improved EFS (P < .0001) and tended to improve OS (P = .0503). Common hematologic AEs included neutropenia (93.8%) and thrombocytopenia (76.9%); severe nonhematologic AEs were rare. Relapses (17/63) predominantly associated with T315I (10/19) and Y253H (5/19) mutations. Age ≥ 35 years, BCR/ABL1P210, and ABL1 Y253H mutation were significantly associated with worse OS. Meanwhile, female, ABL1 Y253H mutation, ABL1 T315I mutation, and failure with achievement of MMR after the first course of consolidation therapy were risk factors for EFS. CONCLUSIONS: Flumatinib-based regimens demonstrated high efficacy and tolerable toxicity in Ph+ ALL, which was comparable to other second-generation TKIs. T315I and Y253H mutations were key drivers of relapse. Although allo-HSCT enhanced survival, longer follow-up period and prospective trials are warranted to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Combined Chemotherapy ProtocolsProtein Kinase InhibitorsHumansFemaleMaleAdultMiddle AgedRetrospective StudiesYoung AdultAgedAdolescentTreatment OutcomePhiladelphia Chromosome

Stichwörter der Autor:innen

BCR-ABL1Philadelphia chromosomeTyrosine kinase inhibitor

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China.
  • National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China; Soochow Hopes Hematology Hospital, Suzhou, China.
  • National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China; Soochow Hopes Hematology Hospital, Suzhou, China. Electron…

Zitieren

APA

Zhang, Z., Yin, J., Wang, J., He, X., Hu, X., Huang, H., Liu, L., Miao, M., Wang, Y., Qiu, H., Tang, X., Wu, D., Ma, X., & Li, W. (2025). Real-world Efficacy and Safety of Flumatinib as the First-line Treatment in Patients With de novo Philadelphia-positive Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.04.010

Vancouver

Zhang Z, Yin J, Wang J, He X, Hu X, Huang H, et al. Real-world Efficacy and Safety of Flumatinib as the First-line Treatment in Patients With de novo Philadelphia-positive Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.04.010

BibTeX
@article{Zhang2025,
  author = {Zhang, Zhibo and Yin, Jia and Wang, Jun and He, Xuefeng and Hu, Xiaohui and Huang, Haiwen and Liu, Limin and Miao, Miao and Wang, Ying and Qiu, Huiying and Tang, Xiaowen and Wu, Depei and Ma, Xiao and Li, Weiyang},
  title = {Real-world Efficacy and Safety of Flumatinib as the First-line Treatment in Patients With de novo Philadelphia-positive Acute Lymphoblastic Leukemia},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.04.010}
}
Kostenlos starten →